{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:36:32Z","timestamp":1793730992023,"version":"4.6.1"},"reference-count":41,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Associazione Italiana per la Ricerca sul Cancro (AIRC)","award":["21198"],"award-info":[{"award-number":["21198"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>A deep and stable molecular response (DMR) is a prerequisite for a successful treatment-free remission (TFR) in chronic myeloid leukemia (CML). In order to better identify and analyze potential candidates of successful TFR, we examined the phenotypic and functional host immune compartment in DMR patients who had received TKI treatment only (TKI-only) or had been previously treated with interferon-alpha (IFN\u03b1 + TKI) or had received IFN\u03b1 treatment only (IFN\u03b1-only). The T\/NK-cell subset distribution, NK- and T-cell cytokine production, activation and maturation markers were measured in 44 patients in DMR treated with IFN\u03b1 only (9), with IFN\u03b1 + TKI (11) and with TKI-only (24). IFN\u03b1 + TKI and TKI-only groups were eligible to TKI discontinuation according to the NCCN and ESMO guidelines (stable MR4 for more than two years). In IFN\u03b1-treated patients, we documented an increased number of lymphocytes capable of producing IFN\u03b3 and TNF\u03b1 compared to the TKI-only group. In INF\u03b1 + TKI patients, the percentage of NKG2C expression and its mean fluorescence intensity were significantly higher compared to the TKI-only group and to the INF\u03b1-only group in the CD56dim\/CD16+ NK cell subsets (INF\u03b1 + TKI vs. TKI-only p = 0.041, p = 0.037; INF\u03b1 + TKI vs. INF\u03b1-only p = 0.03, p = 0.033, respectively). Furthermore, in INF\u03b1-only treated patients, we observed an increase of NKp46 MFI in the CD56bright\/CD16- NK cell subset that becomes significant compared to the INF\u03b1 + TKI group (p = 0.008). Our data indicate that a previous exposure to IFN\u03b1 substantially and persistently modified the immune system of CML patients in memory T lymphocytes, differentiated NKG2C+ \u201clong-lived\u201d NK cells responses, even years after the last IFN\u03b1 contact.<\/jats:p>","DOI":"10.3390\/jcm11195594","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T01:41:58Z","timestamp":1664156518000},"page":"5594","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Immunomodulatory Effects of IFN\u03b1 on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1948-8515","authenticated-orcid":false,"given":"Maria Cristina","family":"Puzzolo","sequence":"first","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Policlinico Umberto 1, \u2018Sapienza\u2019 University, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1163-6162","authenticated-orcid":false,"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Policlinico Umberto 1, \u2018Sapienza\u2019 University, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Mariglia","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Policlinico Umberto 1, \u2018Sapienza\u2019 University, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gioia","family":"Colafigli","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Policlinico Umberto 1, \u2018Sapienza\u2019 University, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Pepe","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Policlinico Umberto 1, \u2018Sapienza\u2019 University, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Scalzulli","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Policlinico Umberto 1, \u2018Sapienza\u2019 University, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Mariggi\u00f2","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Policlinico Umberto 1, \u2018Sapienza\u2019 University, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Latagliata","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Policlinico Umberto 1, \u2018Sapienza\u2019 University, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Guarini","sequence":"additional","affiliation":[{"name":"Hematology, Department of Molecular Medicine, \u2018Sapienza\u2019 University, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Fo\u00e0","sequence":"additional","affiliation":[{"name":"Hematology, Department of Translational and Precision Medicine, Policlinico Umberto 1, \u2018Sapienza\u2019 University, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life Expectancy of Patients with Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population","volume":"34","author":"Bower","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7534","DOI":"10.18632\/oncotarget.23691","article-title":"Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib","volume":"9","author":"Breccia","year":"2017","journal-title":"Oncotarget"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1600-0609.2010.01501.x","article-title":"Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy","volume":"85","author":"Rohon","year":"2010","journal-title":"Eur. J. Haematol."},{"key":"ref_6","first-page":"137320","article-title":"Changes of immunological profiles in patients with chronic myeloid leukemia in the course of treatment","volume":"2010","author":"Sterzl","year":"2010","journal-title":"Clin. Dev. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/imm.12036","article-title":"The immunosuppressive tumour network: Myeloid-derived suppressor cells, regulatory T cells and natural killer T cells","volume":"138","author":"Lindau","year":"2013","journal-title":"Immunology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s13238-020-00707-9","article-title":"Memory T cells: Strategies for optimizing tumor immunotherapy","volume":"11","author":"Liu","year":"2020","journal-title":"Protein Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s40425-018-0399-6","article-title":"Resident memory T cells, critical components in tumor immunology","volume":"6","author":"Blanc","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"317ra198","DOI":"10.1126\/scitranslmed.aac8265","article-title":"Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory","volume":"7","author":"Oliveira","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"273ra13","DOI":"10.1126\/scitranslmed.3010314","article-title":"In vivo tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cells","volume":"7","author":"Biasco","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nri.2015.9","article-title":"Natural killer cell memory in infection, inflammation and cancer","volume":"16","author":"Cerwenka","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"R817","DOI":"10.1016\/j.cub.2013.07.015","article-title":"Evidence for natural killer cell memory","volume":"23","author":"Marcus","year":"2013","journal-title":"Curr. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/eji.201546179","article-title":"Coordinated expansion of both memory T cells and NK cells in response to CMV infection in humans","volume":"46","author":"Bayard","year":"2016","journal-title":"Eur. J. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/leu.2011.239","article-title":"NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice","volume":"26","author":"Chen","year":"2012","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3324\/haematol.2017.165001","article-title":"Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: The IMMUNOSTIM study","volume":"102","author":"Rea","year":"2017","journal-title":"Haematologica"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/leu.2016.360","article-title":"Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia","volume":"31","author":"Ilander","year":"2017","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1007\/s00277-015-2326-y","article-title":"The interferon-alpha revival in CML","volume":"94","author":"Talpaz","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.6004\/jnccn.2016.0162","article-title":"NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017","volume":"14","author":"Pallera","year":"2016","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Hochhaus","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3389\/fimmu.2017.00469","article-title":"Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission","volume":"8","author":"Hughes","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients with Chronic Myeloid Leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): A prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1073\/pnas.0813192106","article-title":"Cytokine-induced memory-like natural killer cells","volume":"106","author":"Cooper","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/ni1332","article-title":"T cell- and B cell-independent adaptive immunity mediated by natural killer cells","volume":"7","author":"Goodarzi","year":"2006","journal-title":"Nat. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.4049\/jimmunol.1201964","article-title":"Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen","volume":"189","author":"Foley","year":"2012","journal-title":"J. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1084\/jem.188.5.953","article-title":"Molecular cloning of NKp46: A novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity","volume":"188","author":"Pessino","year":"1998","journal-title":"J. Exp. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/(SICI)1521-4141(199905)29:05<1656::AID-IMMU1656>3.0.CO;2-1","article-title":"NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells","volume":"29","author":"Sivori","year":"1999","journal-title":"Eur. J. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.4049\/jimmunol.1102461","article-title":"Recognition and prevention of tumor metastasis by the NK receptor NKp46\/NCR1","volume":"188","author":"Glasner","year":"2012","journal-title":"J. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients","volume":"86","author":"Kolb","year":"1995","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/79526","article-title":"Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia","volume":"6","author":"Molldrem","year":"2000","journal-title":"Nat. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"567","DOI":"10.4049\/jimmunol.164.2.567","article-title":"IFN-alpha-expressing tumor cells enhance generation and promote survival of tumor-specific CTLs","volume":"164","author":"Hiroishi","year":"2000","journal-title":"J. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1084\/jem.189.3.521","article-title":"Type I interferons keep activated T cells alive","volume":"189","author":"Marrack","year":"1999","journal-title":"J. Exp. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/jlb.64.3.358","article-title":"Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells","volume":"64","author":"Paquette","year":"1998","journal-title":"J. Leukoc. Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1182\/blood.V99.9.3263","article-title":"Type I interferons produced by dendritic cells promote their phenotypic and functional activation","volume":"99","author":"Montoya","year":"2002","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood-2002-02-0659","article-title":"Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia","volume":"101","author":"Burchert","year":"2003","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/leu.2015.45","article-title":"Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia","volume":"29","author":"Burchert","year":"2015","journal-title":"Leukemia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Bassan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1182\/blood.2021011822","article-title":"Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab","volume":"138","author":"Puzzolo","year":"2021","journal-title":"Blood"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/19\/5594\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:38:06Z","timestamp":1760143086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/19\/5594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,23]]},"references-count":41,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["jcm11195594"],"URL":"https:\/\/doi.org\/10.3390\/jcm11195594","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,23]]}}}